All In Biotech

NDA 021098 · Bayer Hlthcare

Yasmin

Drospirenone, Ethinyl Estradiol · Oral-28

Novel

Last checked: Nov 20, 2026Latest source record: May 19, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

May 11, 2001

Approved uses

3

Original approval plus efficacy supplements

Registered trials

146

48 Phase 3, 7 recruiting

FAERS reports

24,602

21,826 serious, 428 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications ( 4 )] . WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. • Women over 35 years old who smoke should not use Yasmin. ( 4 ) • Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. ( 4 )

What it is approved for

From the label in effect May 19, 2023.

Yasmin ® is indicated for use by females of reproductive potential to prevent pregnancy. Yasmin is a combination of drospirenone, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. ( 1 )

Mechanism: COCs lower the risk of becoming pregnant primarily by suppressing ovulation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • YASMIN · DROSPIRENONE 3MG; ETHINYL ESTRADIOL 0.03MG · TABLET, ORAL-28 · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Drospirenone" as an intervention, any sponsor and status, largest first.

All 146 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain8,959
  • injury7,736
  • pulmonary embolism5,825
  • deep vein thrombosis5,609
  • anxiety4,646
  • emotional distress4,574
  • cholecystitis chronic3,785
  • cholelithiasis2,794
  • gallbladder disorder2,760
  • general physical health deterioration2,324
  • abdominal pain1,739
  • nausea1,652

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004199
2005284
2006322
2007329
20081,375
2009705
20101,404
20116,766
20126,083
20133,245
20141,658
2015489
2016267
2017163
2018190
2019188
2020180
2021127
2022144
2023164
2024127
202599
202694

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 314 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.